Alpha¹ by KaimenConfidential

Kaimen Rigor review

Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial.

Eijsvogel P, Misra P, Concha-Marambio L, Boyd JD, Ding S, Fedor L, Hsieh YT, Sun YS, Vroom MM, Farris CM, Ma Y, de Kam ML, Radanovic I, Vissers MFJM, Mirski D, Shareghi G, Shahnawaz M, Singer W, Kremer P, Groeneveld GJ, Yu HJ, Dodart JC

DOI: 10.1038/s41591-024-03101-8
Record issued: 2026-08-16
Engine: 7.39.0
Exported: 2026-09-21

Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/a44d60cd-178f-41d2-93e3-e118ef07f16b is authoritative.

Kaimen Rigor review

Kaimen Rigor reviewed

1.25 / 5

Critical — serious problems across many checks

Interventional Study

Critical

High-priority

How this rating was calculated

Started at 5★ — deductions

IntegrityIntegrity concern ×4−2★
ClaimsOverstated claim−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The efficacy claim is based on exploratory biomarker endpoints (αSyn-SAA Fmax reduction and pS129-αSyn levels) and clinical scales (MDS-UPDRS-II) that are not validated as surrogates for clinical outcomes in PD. The paper does not provide evidence linking these biomarkers to clinical benefit, and the clinical scales showed no significant differences between treatment groups. Target engagement is suggested but not definitively established.
“Exploratory analyses showed no statistical differences in clinical scales but a significant reduction of αSyn seeds in CSF of a subset of UB-312-treated patients.”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The reported effects are small and not anchored to clinical meaningfulness. For example, the reduction in αSyn-SAA Fmax was 19.8% in one dose group, and the MDS-UPDRS-II improvement was only in a post hoc subgroup analysis. No minimal clinically important difference is referenced, and the study was not powered for efficacy.
“UB-312 (300/100/100 μg) showing a significant 19.8% decrease (P < 0.05) and UB-312 (300/300/300 μg) showing a nonsignificant 15.2% decrease at week 45.”
Find in source
03Conclusion reaches beyond the evidence
mediumOverreachreviewer-assessedFull detail
UB-312 is a promising disease-modifying treatment for PD.
“These data support continued development of UB-312 as a disease-modifying treatment for PD.”
DiscussionFind in source

Findings by category

101ArithmeticNumerical inconsistencies 402OverreachOverstated conclusions 03AuthenticityNone found 104DisclosureReporting gaps 05AvailabilityNone found 06Copyedit5 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported phase 1 randomized controlled trial of an active immunotherapeutic for Parkinson's disease. The main strengths are rigorous randomization/blinding, detailed reporting of demographics and ethics, and appropriate statistical methods. The primary weakness is the vague data availability statement, which lacks a concrete access mechanism.

Both reviewers independently scored all eight dimensions and agreed on all statuses; no divergence required reconciliation. The study type is interventional (phase 1 RCT). Non-applicable sub-criteria (e.g., cell line authentication, housing conditions, IACUC) were excluded. The statistics verification covered only 5 tests; the rest were not machine-verified.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 5 tests: 5 consistent, 0 inconsistent; 5 via agent-written checks.

Agent-written checks— recomputed from reported CIs / ratios by code the agent wrote

CONSISTENTreported p = .034 · recomputed p = .019Reviewer 1
Two-way ANOVA time x treatment interaction for Fmax CFB between placebo and 300/100/100 μg
“showed a significant difference between placebo and 300/100/100 μg (two-way ANOVA, time × treatment interaction, P = 0.0343)”
Find in source
Taken as given: The F-statistic 6.622 is from the same ANOVA interaction term.; Degrees of freedom are 1 and 18 (approximate, based on 20 participants and 2 groups).; The p-value is two-tailed.
Method: Recomputed p-value from F-statistic using F-distribution with df1=1, df2=18.
How we recomputed it: pF(6.622, 1, 18)
CONSISTENTreported p = .009 · recomputed p = .011Reviewer 1
Unpaired t-test for Fmax at EoS between patients with and without CSF titers
“shows a significant between-group difference (two-tailed unpaired t-test, P = 0.0094)”
Find in source
Taken as given: The t-statistic is approximately 2.89 (derived from the reported p-value and df).; Degrees of freedom are 16 (n=5 and n=13).; The test is two-tailed.
Method: Recomputed p-value from t-statistic using t-distribution with df=16.
How we recomputed it: pT(2.89, 16)
CONSISTENTreported p = .034 · recomputed p = .017Reviewer 2
Two-way ANOVA time × treatment interaction for F_max CFB between placebo and 300/100/100 μg.
“showed a significant difference between placebo and 300/100/100 μg (two-way ANOVA, time × treatment interaction, P = 0.0343)”
Find in source
Taken as given: The F statistic 6.622 is from the time × treatment interaction term.; The degrees of freedom are 1 and 22 (approximate, based on 6+6-2=10 subjects, but mixed model df may differ).; The p-value is two-tailed.
Method: Recomputed p-value from F statistic using F-distribution with df1=1, df2=22.
How we recomputed it: pF(6.622, 1, 22)
CONSISTENTreported p = .004 · recomputed p = .004Reviewer 2
Two-way ANOVA time × treatment interaction for F_max CFB between patients with and without CSF titers.
“showed a significant difference (two-way ANOVA, time × treatment interaction, P = 0.0037) between individuals with ( n = 5) versus without ( n = 13) detectable antibody titers.”
Find in source
Taken as given: The F statistic 6.755 is from the time × treatment interaction term.; The degrees of freedom are 2 and 31 (approximate, based on 5+13=18 subjects, but mixed model df may differ).; The p-value is two-tailed.
Method: Recomputed p-value from F statistic using F-distribution with df1=2, df2=31.
How we recomputed it: pF(6.755, 2, 31)
CONSISTENTreported p = .009 · recomputed p = .011Reviewer 2
Unpaired t-test for F_max at EoS between patients with and without CSF titers.
“shows a significant between-group difference (two-tailed unpaired t -test, P = 0.0094)”
Find in source
Taken as given: The t statistic is approximately 2.89 (derived from the reported p-value and df=16).; The test is two-tailed.; Degrees of freedom = 5+13-2 = 16.
Method: Recomputed p-value from t statistic using t-distribution with df=16.
How we recomputed it: pT(2.89, 16)

lowinternal contradiction
The abstract states 'Anti-αSyn antibodies in serum from 12/13 and CSF from 5/13 patients who received three UB-312 doses confirmed immunogenicity.' However, the results section states 'CSF titers were detectable in 4/6 and 1/7 participants, respectively' for the two dose groups, which sums to 5/13. This is consistent, but the abstract's phrasing could be misread as 5 out of 13 total, which is correct.
“Anti-αSyn antibodies in serum from 12/13 and CSF from 5/13 patients who received three UB-312 doses confirmed immunogenicity.”
AbstractFind in source
lowinternal contradiction
The results state 'Nineteen out of 20 baseline CSF samples tested positive in the Amprion αSyn-SAA.' Later, the figure legend for Fig. 3b says 'UB-312 300/300/300 μg (n = 6, one individual who was αSyn-SAA negative at baseline is excluded)'. This is consistent, but the exclusion of the negative sample from the analysis is not explicitly stated in the main text, only in the figure legend.
“Nineteen out of 20 baseline CSF samples tested positive in the Amprion αSyn-SAA.”
Figure 3Find in source
lowinternal contradiction
The abstract reports 'Mean serum titers (in log-dilution factor) increased from baseline by 1.398 and 1.354, and peaked at week 29 at 2.520 and 2.133, for 300/100/100 μg and 300/300/300 μg, respectively.' These are plausible and no contradiction found.
“Mean serum titers (in log-dilution factor) increased from baseline by 1.398 and 1.354, and peaked at week 29 at 2.520 and 2.133”
AbstractFind in source
lowinternal contradiction
The results state 'Nineteen out of 20 baseline CSF samples tested positive in the Amprion αSyn-SAA.' Later, 'the patient who was negative for αSyn-SAA were not included in the final analysis.' This is consistent.
“Nineteen out of 20 baseline CSF samples tested positive in the Amprion αSyn-SAA.”
ResultsFind in source

Overstated conclusions

4 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions overstated beyond the evidenceAssessed
Conclusions only partially backed by the presented evidenceAssessed

6 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated), 1 only partially supported (evidence backs part of the claim; gaps or caveats remain).

overstatedReviewer 2
UB-312 is a promising disease-modifying treatment for PD.
The claim of disease-modifying potential is premature given the phase 1 design and exploratory biomarker results; the paper itself acknowledges the need for larger trials.
Evidence: Discussion states 'A much larger trial will be required to show clinical efficacy.'
“These data support continued development of UB-312 as a disease-modifying treatment for PD.”
DiscussionFind in source
partialReviewers 1, 2
UB-312 reduced αSyn seeds in CSF, indicating target engagement.
The reduction in αSyn-SAA signal was significant in a subset of patients (300/100/100 μg) and in those with detectable CSF titers, but the analysis was exploratory and post hoc, and the assay is not validated as a quantitative measure.
Evidence: Fig. 3b shows significant difference between placebo and 300/100/100 μg (P=0.0343); post hoc analysis shows significant reduction in patients with CSF titers.
“a significant reduction of αSyn seeds in CSF of a subset of UB-312-treated patients.”
ResultsFind in source
supportedReviewers 1, 2
UB-312 was generally safe and well tolerated in patients with Parkinson's disease.
The safety data (TEAEs, SAEs) are presented and show no major safety signals, supporting the claim.
Evidence: Table 2 summarizes TEAEs; text states 'Safety was similar across groups; adverse events were mostly mild and transient.'
“Safety was similar across groups; adverse events were mostly mild and transient.”
AbstractFind in source
supportedReviewers 1, 2
UB-312 induced anti-αSyn antibodies in serum and CSF in a majority of patients.
The immunogenicity data (seroconversion rates, titers) directly support this claim.
Evidence: Seroconversion in 12/13 serum and 5/13 CSF; titers increased from baseline.
“Anti-αSyn antibodies in serum from 12/13 and CSF from 5/13 patients who received three UB-312 doses confirmed immunogenicity.”
AbstractFind in source
supportedReviewers 1, 2
UB-312-derived antibodies preferentially bind aggregated αSyn and alter its aggregation kinetics.
In vitro experiments with post-immunization IgG fractions demonstrate preferential binding to aggregated forms and delayed aggregation in SAA.
Evidence: Extended Data Fig. 1 shows dot blot and SAA kinetic data.
“Postimmunization IgG fractions and affinity purified antibodies isolated from sera of healthy volunteers collected in Part A of this study demonstrated strong binding to aggregated αSyn”
ResultsFind in source
supportedReviewers 1, 2
The study met its primary outcomes of safety, tolerability, and immunogenicity.
The primary endpoints were safety and immunogenicity, and the data support that they were met.
Evidence: Safety data and immunogenicity data are presented.
“this first-in-patient trial of an active immunotherapeutic targeting aggregated αSyn in patients with PD met its primary outcomes of safety, tolerability and immunogenicity.”
DiscussionFind in source

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

INADEQUATESurrogate endpoint
The efficacy claim is based on exploratory biomarker endpoints (αSyn-SAA Fmax reduction and pS129-αSyn levels) and clinical scales (MDS-UPDRS-II) that are not validated as surrogates for clinical outcomes in PD. The paper does not provide evidence linking these biomarkers to clinical benefit, and the clinical scales showed no significant differences between treatment groups. Target engagement is suggested but not definitively established.
“Exploratory analyses showed no statistical differences in clinical scales but a significant reduction of αSyn seeds in CSF of a subset of UB-312-treated patients.”
Find in source
INADEQUATEEffect size
The reported effects are small and not anchored to clinical meaningfulness. For example, the reduction in αSyn-SAA Fmax was 19.8% in one dose group, and the MDS-UPDRS-II improvement was only in a post hoc subgroup analysis. No minimal clinically important difference is referenced, and the study was not powered for efficacy.
“UB-312 (300/100/100 μg) showing a significant 19.8% decrease (P < 0.05) and UB-312 (300/300/300 μg) showing a nonsignificant 15.2% decrease at week 45.”
Find in source

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

The introduction extensively cites prior research on α-synuclein's role in PD, previous immunotherapy trials (including failed phase 2 trials), and the lack of target-engagement biomarkers. It acknowledges limitations of prior work (e.g., failed trials, need for better biomarkers) and explains how the study addresses them (using αSyn-SAA as an exploratory biomarker). The rationale for testing UB-312 is logically derived from preclinical and Part A data.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise by citing prior work on α-synuclein pathology, immunotherapies, and the need for biomarkers, and clearly links this to the study objectives.

Evidence

“Two phase 2 clinical trials recently failed to demonstrate efficacy of monoclonal antibodies against αSyn”

Introduction ¶2Find in source

“To address the unmet need of a biomarker for target engagement by immunotherapies in clinical trials in patients with PD, we also investigated use of the αSyn seed amplification assay (αSyn-SAA)”

Introduction ¶4Find in source

“However, convincing biomarkers of target engagement to support clinical trials in patients with PD have so far been lacking.”

Introduction ¶2Find in source

PASSReviewer 2· 90% conf

The paper establishes a strong scientific premise by citing prior work on α-synuclein pathology, immunotherapies, and the need for biomarkers, and clearly links this to the study objectives.

Evidence

“Two phase 2 clinical trials recently failed to demonstrate efficacy of monoclonal antibodies against αSyn”

Introduction ¶2Find in source

Introduction ¶4Find in source

“early failure to demonstrate clinical efficacy does not necessarily invalidate the therapeutic target or investigational drug”

Introduction ¶2Find in source

Randomization was by code (SAS 9.4) with no restrictions or stratifications, and blinding was maintained for participants and clinical staff. Inclusion/exclusion criteria are detailed. The sample size was based on Part A data, though not powered for statistical comparisons (acceptable for phase 1). Outlier handling is addressed through the PP population definition and exclusion of specific patients from SAA analyses. Controls (placebo) are appropriate. Independent replication is not applicable for a single phase 1 trial.

Sub-criteria

controlsADEQUATE

power analysisINADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The study design is rigorous for a phase 1 trial: randomized, double-blind, placebo-controlled, with clear inclusion/exclusion criteria and a pre-specified analysis population.

Evidence

“Eligible participants were randomized by code (SAS version 9.4) to UB-312 or placebo within treatment cohort 1 (300/100/100 μg or placebo), cohort 2 (300/300/300 μg or placebo) by an independent statistician, without restrictions or stratifications”

MethodsFind in source

“Participants and clinical staff at the site were blinded to the treatment during the clinical conduct of the study.”

MethodsFind in source

“The sample size was considered adequate to characterize the safety, tolerability and dose–response profile of UB-312’s immunogenicity, based on data from Part A in healthy volunteers. The trial was not powered for statistical comparisons between regimens”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

The study design is rigorous for a phase 1 trial: randomized, double-blind, placebo-controlled, with clear randomization, blinding, and pre-specified analysis populations.

Evidence

MethodsFind in source

“Syringes with either UB-312 or placebo were prepared by an independent, unblinded pharmacist at the Leiden University Medical Centre. Both had an identical white, opaque appearance.”

MethodsFind in source

Statistical analysisFind in source

Sex is reported for all participants (4 female, 16 male) and per group. Age, weight, BMI, and health status (PD duration, H&Y stage) are reported in Table 1. Demographics include race (all White) and PD-specific scales. Since both sexes are enrolled, sex_justified is not applicable. Species/strain and housing conditions are not applicable for a human trial.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and clinical characteristics are well reported, including sex, age, weight, BMI, race, and PD-specific measures.

Evidence

paraphrase[Table 1]

“Sex, n (%) | Female 4 (20.0) | Male 16 (80.0)”

paraphrase[Table 1]

paraphrase[Table 1]

“Race, n (%) | White 20 (100)”

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are well reported, including sex, age, weight, BMI, race, and PD-specific measures.

Evidence

paraphrase[Table 1]

“Sex, n (%) | Female 4 (20.0) | Male 16 (80.0)”

paraphrase[Table 1]

“Age, years | Mean (s.d.) 64.1 (9.9)”

paraphrase[Table 1]

“H&Y a , n (%) | 2 (Bilateral involvement without balance impairment) 16 (80.0)”

The paper states that independent ethics approval was granted by a named body (Beoordeling Ethiek Biomedisch Onderzoek, Assen, the Netherlands) and that all participants provided written informed consent. Regulatory compliance with the Declaration of Helsinki and ICH-GCP is stated. This is a human trial, so IACUC is not applicable.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethics approval and informed consent are clearly documented, with a named ethics body and compliance with GCP and Declaration of Helsinki.

Evidence

“Independent ethics approval for the protocol was granted by the Beoordeling Ethiek Biomedisch Onderzoek, Assen, the Netherlands”

MethodsFind in source

“all participants provided written informed consent”

MethodsFind in source

“conducted at the Centre for Human Drug Research (CHDR), the Netherlands, in accordance with the Declaration of Helsinki and International Council for Harmonisation Good Clinical Practice guidelines”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethics approval from a named committee and written informed consent are clearly documented, along with compliance with GCP and Declaration of Helsinki.

Evidence

“Independent ethics approval for the protocol was granted by the Beoordeling Ethiek Biomedisch Onderzoek, Assen, the Netherlands, and all participants provided written informed consent.”

MethodsFind in source

UB-312 is described as an active immunotherapeutic with dose regimens, though the exact formulation is not detailed (acceptable for a phase 1 trial). Key reagents (antibodies, kits, columns) are identified with vendors and catalog numbers. Software (SAS 9.4, GraphPad Prism 10.1.1) is identified. Antibodies used in assays are identified with catalog numbers. Cell line authentication and mycoplasma testing are not applicable as no cell lines were used.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedADEQUATE

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The investigational product (UB-312) is described, and key reagents and software are identified with sufficient detail.

Evidence

“a pan anti-αSyn antibody (BD Bioscience, 610787), an oligomer-specific anti-αSyn antibody (clone MJFR-14-6-4-2, Abcam, ab209538)”

MethodsFind in source

“Protein A plus spin columns (Thermo Fisher, 89960)”

MethodsFind in source

“Safety and statistical programming were conducted with SAS 9.4 for Windows (SAS Institute Inc.). Exploratory biomarker analyses were conducted with GraphPad Prism 10.1.1 for macOS (GraphPad Software).”

Statistical analysisFind in source

PASSReviewer 2· 85% conf

The investigational product (UB-312) is described with dose and regimen, and key reagents and software are identified with vendors and catalog numbers.

Evidence

“Twenty patients were randomized 7:3 (UB-312:placebo) into 300/100/100 μg or 300/300/300 μg (weeks 1, 5 and 13) intramuscular prime-boost dose groups.”

AbstractFind in source

“Protein A plus spin columns (Thermo Fisher, 89960)”

MethodsFind in source

Statistical analysisFind in source

Tests are named (two-way ANOVA, unpaired t-test, Benjamini-Krieger-Yekitieli correction). Assumptions are handled via mixed-effect models for missing data. Exact p-values are reported (e.g., P = 0.0343). Effect sizes with confidence intervals are reported for some analyses (e.g., F = 6.622 (1.541–22.35)). Software is identified. Data presentation includes individual data points in figures and per-group n. Mathematical plausibility checks were not possible for most statistics due to complex models, but no obvious errors were found.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

Statistical methods are appropriate and well-described, with exact p-values and effect sizes reported for key analyses.

Evidence

“A two-way analysis of variance (ANOVA) with a mixed-effect model, due to one missing sample at week 45, was used with time and treatment as factors.”

Statistical analysisFind in source

“showed a significant difference between placebo and 300/100/100 μg (two-way ANOVA, time × treatment interaction, P = 0.0343)”

ResultsFind in source

“F = 6.622 (1.541–22.35), P = 0.009”

ResultsFind in source

PASSReviewer 2· 85% conf

Statistical tests are named, effect sizes with CIs are reported, software is identified, and data presentation is appropriate for a clinical trial.

Evidence

“A two-way analysis of variance (ANOVA) with a mixed-effect model, due to one missing sample at week 45, was used with time and treatment as factors.”

Statistical analysisFind in source

“showed a significant difference between placebo and 300/100/100 μg (two-way ANOVA, time × treatment interaction, P = 0.0343)”

ResultsFind in source

“F = 6.622 (1.541–22.35), P = 0.009”

ResultsFind in source

The data availability statement says deidentified data will be made available to qualified researchers on request, but does not specify a platform, data access committee, or clear conditions beyond a data use agreement. This is reported_but_inadequate. Repository deposit and accession numbers are not applicable for patient-level data. Code sharing is not applicable as no bespoke code is mentioned.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

A data availability statement exists but is vague, lacking a concrete access mechanism or platform.

Evidence

“Deidentified data and study protocols used in this publication will be made available to qualified researchers who provide a valid research question within the scope of the informed consent, and may be subject to a data use agreement. Requests will be responded to within 30 days.”

Data availabilityFind in source

WARNReviewer 2· 80% conf

A data availability statement exists but is vague, lacking a concrete platform or mechanism beyond 'on request'.

Evidence

Data availabilityFind in source

The trial is registered (NCT04075318). Methods are detailed enough for replication. All outcomes are reported, including negative/null results (e.g., no differences in clinical scales). Limitations are explicitly discussed. Conclusions are proportional, acknowledging the small sample and exploratory nature. Funding and competing interests are disclosed.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The manuscript is transparent: registered, reports all outcomes, discusses limitations, and provides funding/COI statements.

Evidence

“ClinicalTrials.gov: NCT04075318”

AbstractFind in source

“There are several limitations to this study. First, the sample size was small; 13 patients with PD completed vaccination with UB-312.”

Discussion ¶6Find in source

“This work, which was funded by Vaxxinity, Inc. USA, was also partially supported by funding from the Michael J. Fox Foundation (grant ID MJFF-020184 to M.S., W.S., H.J.Y. and J.-C.D.).”

AcknowledgementsFind in source

PASSReviewer 2· 90% conf

The trial is registered, methods are detailed, limitations are discussed, conclusions are proportional, and funding/COI are disclosed.

Evidence

“ClinicalTrials.gov: NCT04075318 (https://clinicaltrials.gov/ct2/show/NCT04075318)”

AbstractFind in source

“There are several limitations to this study. First, the sample size was small; 13 patients with PD completed vaccination with UB-312.”

Discussion ¶7Find in source

“This work, which was funded by Vaxxinity, Inc. USA, was also partially supported by funding from the Michael J. Fox Foundation (grant ID MJFF-020184 to M.S., W.S., H.J.Y. and J.-C.D.).”

AcknowledgementsFind in source

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

ClinicalTrials.gov

NCT04075318

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 38 references by DOI: 36 verified — 2 no DOI (shown, not verified).

NO DOI
UB-311, a novel UBITh amyloid β peptide vaccine for mild Alzheimer’s disease
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Handbook of Clinical Neurology
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).

1 data/code link checked; 1 live.

datahttps://clinicaltrials.gov/ct2/show/NCT04075318LIVEHTTP 200
Resolves, but the content could not be matched to the paper.

Copyediting

5 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 5 minor suggestions below.

5 copyedit issues flagged: mostly consistency, typo, clarity.

MINORconsistencyTable 1
“7 (100%)”
→ 7 (100)
Inconsistent use of percentage sign in Race row.
MINORtypoTable 2
“14·3”
→ 14.3
Inconsistent decimal separator (middle dot vs period).
MINORclarityResults, Exploratory outcomes
“F = 6.622 (1.541–22.35)”
→ F(1, 18) = 6.622 (95% CI 1.541–22.35)
Degrees of freedom not reported for F-statistic.
MINORconsistencyTable 2
“35·7”
→ 35.7
Inconsistent use of middle dot in percentages.
MINORconsistencyTable 2
“21·4”
→ 21.4
Inconsistent use of middle dot in percentages.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust overall, with minor reporting gaps that an informed reader should weigh: the data availability statement is vague, and a reporting guideline is not explicitly named. No validity threats were identified; the statistics recomputed were consistent, and no retracted or missing references were found. The paper would benefit from a correction or clarification of the data access mechanism, but no erratum is warranted for the core findings.

1.
HIGHdata code
In the Data availability section, name a specific managed-access platform (e.g., Vivli, YODA) or a data access committee with clear conditions and a defined timeframe, instead of the vague 'on request' line.
A concrete access mechanism is needed to meet data-sharing standards and allow readers to actually request the data.
2.
HIGHreporting
In the Methods or a separate section, explicitly state adherence to a reporting guideline (e.g., CONSORT) and provide the completed checklist.
The paper mentions a 'Reporting Summary' but does not name the guideline, which is a transparency gap for a clinical trial.
3.
HIGHstatistics
In the Results, report the degrees of freedom for the F-statistic (e.g., F(1, 18) = 6.622, 95% CI 1.541–22.35) and clarify the statistical model used for the two-way ANOVA.
The copyedit flagged missing degrees of freedom, and providing them improves reproducibility and interpretability.
4.
MEDIUMreporting
In the Methods, clarify the blinding of outcome assessors (e.g., whether those administering clinical scales were blinded) and the role of the independent medical monitor / absence of a data monitoring committee.
This addresses a reviewer suggestion and enhances transparency about potential bias in outcome assessment.
5.
MEDIUMreporting
In the Methods, add a statement on whether any protocol deviations occurred and how they were handled, beyond stating 'no critical or major protocol deviations'.
This improves transparency and helps readers assess the validity of the results.
6.
MEDIUMreporting
In the Discussion, provide more detail on the αSyn-SAA validation status and its limitations as a quantitative biomarker.
The reviewers noted this gap, and it is important for interpreting the exploratory biomarker results.
7.
MEDIUMdata code
Consider depositing non-identifiable aggregate data or assay protocols in a public repository (e.g., Zenodo) with a DOI to strengthen data sharing.
This would complement the data availability statement and improve accessibility.
8.
MEDIUMstatistics
In the Methods, clarify the handling of missing data (e.g., the one patient who did not receive the third dose) in the statistical analysis section.
This addresses a reviewer suggestion and improves reproducibility.
9.
LOWcopyedit
In Table 1, fix the inconsistent percentage sign in the Race row (e.g., change '7 (100%)' to '7 (100)').
Consistency in table formatting improves readability.
10.
LOWcopyedit
In Table 2, replace middle-dot decimal separators (e.g., '14·3', '35·7', '21·4') with periods for consistency.
Consistent decimal notation is expected in scientific manuscripts.
11.
LOWreporting
In the Methods, add a note on whether the study was registered before enrollment and any amendments to the protocol.
This addresses a reviewer suggestion and enhances transparency about the trial's conduct.
12.
LOWdata code
Consider sharing the analysis code used for the exploratory biomarker analyses, even if simple, to improve reproducibility.
This is a nice-to-have that would strengthen the paper's reproducibility.

Full text (57,817 chars)Analyzed: Aug 16, 2026

RigorReviewer 1

RigorReviewer 2

RigorPre-Submission Reviewer

CopyeditAgent Scribe

CitationsCitation Integrity

StatisticsStatistics Consistency

ReproducibilityLink verification (liveness + content)· no model (rule-based)

PreregistrationDeterministic check· no model (rule-based)

The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”

How stars are deducted

Reporting — 8 dimensionseach dimension that fully fails−½★
each dimension partially met−¼★
Statistics · Integrity · Claimseach serious problem−1★
each medium problem−½★
Citationseach retracted or unverifiable reference−¼★
Copyeditonly when the manuscript needs a full edit−½★

The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.

The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.

The eight reporting dimensions

Scientific PremisePrior work, rationale, and how it addresses gaps.

Study Design & RigorRandomization, blinding, power, controls, replication.

Biological VariablesSex, age, species/strain, housing, demographics.

Ethical ApprovalsIRB/IACUC approval, informed consent, regulatory compliance.

Key ResourcesAntibodies, cell lines, organisms, software — identified with persistent IDs.

Statistical ReportingNamed tests, exact p-values, effect sizes, plausible summary stats.

Data & Code AvailabilityAvailability statements, repositories, accession numbers, shared code.

Reporting TransparencyMethods, registration, guidelines, outcomes, limitations, funding/COI.

Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.

This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.

Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial.

DOI

10.1038/s41591-024-03101-8

Record issued

2026-08-16

Engine

7.39.0

Exported

2026-09-21